menu
close
This website is intended for Ireland Healthcare Professionals only. Not a Healthcare Professional in Ireland? Click here
menu
close
menu
close

VEOZA™ (fezolinetant) is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.1

VMS are also known as hot flushes and night sweats.2

Woman spraying VEOZA™ (fezolinetant) logo fire extinguisher at VMS fire. Treat the Heat with non-hormonal VEOZA
Brain with captions: Block the binding of NKB, Reduce KNDy neuronal activity, and Balance temperature control centre activity

VEOZA is not a hormone

It is the first-in-class selective neurokinin 3 (NK3) receptor antagonist licensed. It blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron, which is postulated to restore the balance in KNDy neuronal activity in the thermoregulatory centre of the hypothalamus1,3,4

Watch the Mechanism of Action of VEOZA

Click here for the Summary of Product Characteristics for VEOZA (fezolinetant) 

How VEOZA disrupts hot flushes

Temperature control homeostasis showing the KNDy neuron inhibited by oestrogen and stimulated by NKB6

Homeostasis

KNDy neurons in the hypothalamus are inhibited by oestrogen and stimulated by the neuropeptide, NKB. This balance contributes to body temperature regulation.3

Impact of NKB showing how the reduction of oestrogen and unopposed NKB stimulation lead to heightened KNDy neuronal activity

Menopause

Oestrogen decline during menopause disrupts this balance with NKB. Unopposed, NKB signalling causes heightened KNDy neuronal activity.3 This triggers heat dissipation mechanisms, including vasodilation and sweating–VMS.3

VEOZA™ (fezolinetant) inhibits binding of NKB to NK3R on the KNDy neuron

Blocking NKB to reduce heat

VEOZA selectively binds to the NK3 receptor to block NKB.1 This action moderates NKB signalling and KNDy neuron activity, helping to restore thermoregulatory balance and better control VMS.1,3

A legend including Oestrogen, oestrogen receptor alpha, neurokinin B, neurokinin 3 receptor
A legend including Oestrogen, oestrogen receptor alpha, neurokinin B, neurokinin 3 receptor
Image to download VEOZA™ (fezolinetant) Slim Jim
RESOURCE

Download the MOA of VEOZA1,3

Quickly reference how VEOZA disrupts hot flushes.

Discover efficacy and safety in VEOZA clinical trials

Sign up for VEOZA updates and product information

KNDy: kisspeptin/neurokinin B/dynorphin, MOA: mechanism of action, NK3: neurokinin 3, NKB: neurokinin B, ORα, oestrogen receptor alpha, VMS: vasomotor symptoms.


REFERENCES: 1. VEOZA Summary of Product Characteristics. 2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43-55. 3. Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs 2021;30(7):681-94. 4. Jayasena CN, Comninos AN, Stefanopoulou E, et al. Neurokinin B administration induces hot flushes in women. Sci Rep (Epub) 02-16-2015.

Adverse events should be reported. For Ireland, Healthcare professionals are asked to report any suspected adverse reactions via; HPRA Pharmacovigilance, Website: www.hpra.ie or Astellas Pharma Co. Ltd. Tel: +353 1 467 1555, Email: irishdrugsafety@astellas.com

MAT-IE-VEO-2025-00009 March 2025